Keyphrases
Tumor-specific
100%
Vaccination
100%
Cytotoxic T Lymphocytes
100%
B-cell non-Hodgkin Lymphoma (B-NHL)
100%
Cytotoxic T Cell Response
100%
Idiotype
100%
Precursor Frequency
42%
Immune Response
28%
Therapeutic Vaccine
28%
Cytolytic
28%
Human Tumors
14%
Cell-mediated
14%
Clinical Evaluation
14%
Progressive Disease
14%
Tumor Protein
14%
Vaccine Effectiveness
14%
Tumor Antigen
14%
Non-Hodgkin Lymphoma
14%
Minimal Change Disease
14%
Lymphoma Patients
14%
Cellular Immune Response
14%
Protein Antigen
14%
Non-Hodgkin B-cell Lymphoma
14%
Limiting Dilution Analysis
14%
Human Pathogenic Viruses
14%
Medicine and Dentistry
Non-Hodgkin Lymphoma
100%
B Cell
100%
Immunoglobulin Idiotype
100%
Specific Tumor
100%
Cytotoxic T-Cell
100%
Precursor
85%
Diseases
28%
Immune Response
28%
Immunoglobulin
28%
Neoplasm
14%
Vaccine
14%
Progressive Disease
14%
Tumor Vaccine
14%
Cellular Immunity
14%
Tumor Antigen
14%
B-Cell Lymphoma
14%
Clinical Trial
14%
Cancer Antibody
14%
Antigen
14%
Immunology and Microbiology
B Cell
100%
Cytotoxic T Cell
100%
Idiotype
100%
Precursor
85%
Immune Response
28%
Intravenous Immunoglobulin
28%
Vaccine Efficacy
14%
Antigen
14%
Adoptive Immunity
14%
Tumor Vaccine
14%
Dilution
14%
Cancer Antibody
14%
Tumor Antigen
14%
Immunology
14%
Vaccine
14%